BRPI0908848A2 - proteínas híbridas hipoalergênicas dos grupos maiores 1 e 2 de alérgenos de ácaros para uso no tratamento de alergias - Google Patents

proteínas híbridas hipoalergênicas dos grupos maiores 1 e 2 de alérgenos de ácaros para uso no tratamento de alergias

Info

Publication number
BRPI0908848A2
BRPI0908848A2 BRPI0908848A BRPI0908848A BRPI0908848A2 BR PI0908848 A2 BRPI0908848 A2 BR PI0908848A2 BR PI0908848 A BRPI0908848 A BR PI0908848A BR PI0908848 A BRPI0908848 A BR PI0908848A BR PI0908848 A2 BRPI0908848 A2 BR PI0908848A2
Authority
BR
Brazil
Prior art keywords
hybrid proteins
larger groups
mite allergens
allergy treatment
hypoallergenic hybrid
Prior art date
Application number
BRPI0908848A
Other languages
English (en)
Portuguese (pt)
Inventor
Alberto Martinez Garate
Inaki Ibarrola Lopez De Davalillo
Juan Andrés Asturias Ortegas
Maria Carmen Arilla Rodriguez
Original Assignee
Bial Ind Farmacéutica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Ind Farmacéutica S A filed Critical Bial Ind Farmacéutica S A
Publication of BRPI0908848A2 publication Critical patent/BRPI0908848A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0908848A 2008-03-25 2009-03-24 proteínas híbridas hipoalergênicas dos grupos maiores 1 e 2 de alérgenos de ácaros para uso no tratamento de alergias BRPI0908848A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200800827 2008-03-25
PCT/IB2009/005114 WO2009118642A2 (en) 2008-03-25 2009-03-24 Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies

Publications (1)

Publication Number Publication Date
BRPI0908848A2 true BRPI0908848A2 (pt) 2015-12-01

Family

ID=41110539

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908848A BRPI0908848A2 (pt) 2008-03-25 2009-03-24 proteínas híbridas hipoalergênicas dos grupos maiores 1 e 2 de alérgenos de ácaros para uso no tratamento de alergias

Country Status (9)

Country Link
US (2) US8951530B2 (OSRAM)
EP (3) EP2436691B1 (OSRAM)
JP (2) JP5793073B2 (OSRAM)
CN (2) CN101977929B (OSRAM)
BR (1) BRPI0908848A2 (OSRAM)
CA (1) CA2718994C (OSRAM)
ES (2) ES2638271T3 (OSRAM)
MX (1) MX2010010353A (OSRAM)
WO (1) WO2009118642A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011260233C1 (en) * 2010-06-03 2015-04-16 Alk-Abello A/S Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
EP2460824A1 (en) 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
CN102676568A (zh) * 2012-05-08 2012-09-19 崔玉宝 一种生产重组粉尘螨变应原Der f1和Der f2融合蛋白的方法
EP2727934B1 (en) 2012-09-20 2016-06-15 Universidad de Cartagena Fusion proteins with representation of different allergens: vaccine proposal for mite allergies
US10457711B2 (en) * 2014-12-02 2019-10-29 Taiho Pharmaceutical Co., Ltd. Dermatophagoides farinae protein
NL2014882B1 (en) * 2015-05-29 2017-01-31 Citeq B V Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy.
AU2016333474A1 (en) * 2015-09-30 2018-03-22 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
GB201602850D0 (en) * 2016-02-18 2016-04-06 Bial Ind Farmaceutica S A Fusion proteins
CN108265056B (zh) * 2016-12-31 2019-08-30 江苏众红生物工程创药研究院有限公司 一种重组户尘螨1类变应原蛋白及其制备方法和应用
CN109852652B (zh) * 2017-11-30 2023-05-02 江苏众红生物工程创药研究院有限公司 重组尘螨Ⅰ型变应原Der p1和Der f1蛋白的制备与应用
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
CN113831400A (zh) * 2021-07-29 2021-12-24 沈阳医学院 一种尘螨致敏蛋白Der p 1的分离纯化方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362290A4 (en) * 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US7288256B1 (en) 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
EP1221317A1 (en) 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
FR2841906B1 (fr) 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
ATE307141T1 (de) * 2003-01-21 2005-11-15 Biomay Prod & Handel Verfahren zur vorbereitung von hypoallergenen mosaikproteine
CN1780852A (zh) * 2003-04-25 2006-05-31 诺和酶股份有限公司 组1螨多肽变体
ITRM20040103A1 (it) 2004-02-27 2004-05-27 Consiglio Nazionale Ricerche Proteine di fusione comprendenti allergeni della famiglia delle ns-ltps, loro usi e composizioni farmaceutiche che le comprendono.
AT501101B1 (de) * 2004-12-02 2008-01-15 Biomay Ag Protein-allergen-derivat
US20070065468A1 (en) * 2005-08-29 2007-03-22 National University Of Singapore Chimeric allergens for immunotherapy
CN100374152C (zh) * 2005-12-23 2008-03-12 中国农业大学 一种过敏性反应抑制剂
GB0607377D0 (en) 2006-04-12 2006-05-24 Glaxosmithkline Biolog Sa Novel Methods
EP1908777B1 (en) 2006-10-06 2016-02-03 Stallergenes Mite fusion proteins
EP1908776A1 (en) * 2006-10-06 2008-04-09 Stallergenes Sa Mite fusion proteins

Also Published As

Publication number Publication date
JP2011517407A (ja) 2011-06-09
MX2010010353A (es) 2010-10-05
WO2009118642A2 (en) 2009-10-01
CN101977929B (zh) 2016-10-19
ES2638308T3 (es) 2017-10-19
EP2436691A2 (en) 2012-04-04
EP2436692A3 (en) 2012-06-27
US20110052640A1 (en) 2011-03-03
CA2718994A1 (en) 2009-10-01
EP2436692A2 (en) 2012-04-04
CN107118265A (zh) 2017-09-01
EP2436691A3 (en) 2012-06-27
US8951530B2 (en) 2015-02-10
ES2638271T3 (es) 2017-10-19
JP2015164424A (ja) 2015-09-17
WO2009118642A3 (en) 2009-12-03
JP5793073B2 (ja) 2015-10-14
CA2718994C (en) 2017-06-13
EP2436692B1 (en) 2017-08-02
JP6068544B2 (ja) 2017-01-25
US20150152148A1 (en) 2015-06-04
CN101977929A (zh) 2011-02-16
EP2268662A2 (en) 2011-01-05
EP2436691B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
BRPI0908848A2 (pt) proteínas híbridas hipoalergênicas dos grupos maiores 1 e 2 de alérgenos de ácaros para uso no tratamento de alergias
PT2252283T (pt) Triterpenóides sintéticos e métodos de uso no tratamento de doença
IL282772A (en) Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
EP2205196A4 (en) HAIR CARE COMPOSITIONS AND METHODS OF HAIR TREATMENT
EP1951762A4 (en) PREPARATIONS AND METHODS FOR ENHANCED SKIN CARE
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0912402A2 (pt) processos e kit de tratamento dos cabelos
BRPI0821424A2 (pt) curativo para tecido mucoso e método de uso
FR2914852B1 (fr) Composition emulsifiee de type eau-dans-huile et cosmetique la comprenant
BRPI0822997A2 (pt) Extratos imunomoduladores de bactérias lactobacillus e métodos para fabricação e uso dos mesmos
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
SMT201500224B (it) Derivati purinici per l'uso nel trattamento di malattie allergiche, infiammatorie e infettive
BR112012000417A2 (pt) aparelho para uso em tratamento terapêutico e/ou cosmético
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0821499A2 (pt) Artigos de filtração de fluído e métodos de preparo e uso dos mesmos
BRPI1008834A2 (pt) dispositivo compactos de monitoramento fisiológico no corpo e métodos dos mesmos
BRPI0918670A2 (pt) composições e métodos para o tratamento de disordens mediados por ige
BRPI0916269A2 (pt) dispositivo de modificação de tecido e seu método de uso
BRPI0909077A2 (pt) Artigos multicamadas e métodos de preparo e uso dos mesmos
EP2262469A4 (en) SKIN CARE COMPOSITIONS AND METHODS OF USE
BRPI0914752A2 (pt) fórceps ósseo para segurar placas e método de uso
BRPI0919789A2 (pt) metodo para identificar peptídeos e proteínas alergênicas
BRPI0916443A2 (pt) anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos
BRPI1105778A2 (pt) "insersores de dispositivo médico e processos de inserção e uso de dispositivos médicos"
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIAL INDUSTRIAL FARMACEUTICA, S.A (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2507 DE 22-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.